The pathogenesis of avascular necrosis of bone (ANB) was investigated in 111 patients with systemic lupus erythematosus (SLE) (24 with ANB, 87 without ANB); patients' ages, corticosteroid treatment, clinical and laboratory features associated with SLE, and haemostatic profiles were all taken into account. The mean ages of patients with and without ANB at the time of diagnosis of SLE was 24-1 and 31*2 years respectively. The mean maximal daily dose of prednisolone in the group with ANB was 50*8 mg, which was significantly higher than the dose (41*8 mg) in the group without ANB. Disease features of SLE, such as Raynaud's phenomenon, hyperlipidaemia, nephrotic syndrome, hypertension, and disease activity, were not found to be related to ANB. The percentage of patients who had lupus anticoagulant as well as a shorter activated partial thromboplastin time was greater in those with ANB than in those without. Multiple factors may be involved in the pathogenesis of ANB in SLE, and it is suggested that haemostatic abnormalities, which could be influenced by corticosteroids and young ages, play some part in the development of ANB.
Since 1960 when Dubois and Cozen suggested an association of avascular necrosis of bone (ANB) with systemic lupus erythematosus (SLE),1 ANB has continued to be one of the major problems during the course of SLE. Corticosteroids, which are used for most patients with SLE, have been implicated as one cause of ANB, 6 but multiple factors, such as vasculitis,7 8 fat emboli,9 10 Raynaud's phenomenon,6 11 and young ages,12 13 must contribute to its development. As ANB may result from interference with the blood supply,7 haemostatic abnormalities and factors which induce them could also contribute to its occurrence.
In this study we attempted to determine the predisposing factors for ANB in SLE, considering particularly patients' ages, corticosteroid treatment, and haemostatic state.
Accepted for publication 28 tp<OO5. treatment of the 24 patients with ANB. The period between the time of diagnosis of SLE and of ANB ranged from 1.2 to 13 years (mean 4-1). The age of patients with ANB at the time of diagnosis of SLE ranged from 10 to 42-3 years (mean 24-1). This is significantly younger than the age of the group without ANB at the time of diagnosis of SLE, whose mean age was 31-2 years, ranging from 10 to 64 years (p<0-01) ( Table 2 ). Of 24 patients with ANB, SLE was diagnosed in nine (38%) before the age of 20, whereas in the group without ANB only 12/87 (14%) were diagnosed before the age of 20-a significant difference (p<001). Most patients in this study took corticosteroids after the diagnosis of SLE had been established. The dose of prednisolone given at the time of diagnosis of ANB ranged from 0 to 20 mg/day (mean 11-1 mg/day). The mean maximal daily dose of prednisolone in the patients with ANB was 50-8 mg, however, significantly higher than in the group without ANB (p<0-05) ( Tables 1 and 2) .
Factors thought to be associated with the pathogenesis of ANB in SLE were compared in the groups with and without ANB ( Table 3 ). The percentage of patients with hypocomplementaemia and positive anti-dsDNA antibodies, which reflect the disease activity of SLE, was small at the time of diagnosis of ANB and similar to that of patients without ANB. The incidence of Raynaud's phenomenon, which some investigators have suggested is associated with ANB,6 1 was high, but almost the same in patients with and without ANB. The group with ANB had a history of central nervous system involvement, which is considered to reflect vasculitis, also as frequently as the group without ANB. The incidence of hyperlipidaemia was smaller in both groups. Similarly, the incidence of hypertension and thrombocytopenia were similar in both groups. Nephrotic syndrome appeared more prevalent in the group with ANB, but the difference was not significant. Although the maximal daily doses of corticosteroids were different in the two groups, the proportion of patients receiving pulse treatment with 1000 mg/day methylprednisolone or immunosuppressive agents, or both, was the same in both groups. (Table 4) . Table 5 shows the platelet aggregation activity in patients with and without ANB. Patients with SLE were divided into three groups-namely, those whose platelet aggregation was normal, accelerated, or diminished. There was no significant difference in platelet aggregation between the groups with and without ANB. In the patients with ANB, however, the percentage in the 'diminished' group was low tSignificantly higher (p<005). diseases (mainly SLE) had more severe atherosclerosis in the large arteries in the second and third decades of life than the patients without collagen diseases. They also found, surprisingly, that the atherosclerosis index was highest in the second decade of life in patients with SLE, whereas the index increased with age in patients with other diseases. Such changes in arteries in young patients with SLE, probably induced by SLE itself or corticosteroid treatment, or both, may be related to the genesis of ANB. In addition, ischaemic heart disease, probably due to atherosclerosis and arteritis in coronary arteries, is more often observed in young patients with SLE than in normal individuals. 24 There have been various reports in which Raynaud's phenomenon, 6 1 hy?erlipidaemia,9 or central nervous system lupus1 has each been associated with the occurrence of ANB, but there is still controversy about such relations.5 6 We found that the incidence of such features of SLE was no higher in patients with ANB than in those without. Pulse treatment with very high doses of steroids (1000 mg/day) for three days and immunosuppressants were not found to be related to ANB. This may mean that treatment with high doses of steroids for a fairly long period has more influence than very high doses of steroids for a short period on the genesis of ANB. The incidence of ANB is high in renal transplantation, in which very high doses of steroids are given for a longer period of time than in pulse treatment. 2 3 Recent investigations show that lupus anticoagulant, which is often found in the plasma of patients with SLE, is associated with thrombosis. 25 This study suggests that special attention should be paid to the possible development of ANB when young patients with SLE are treated with high doses of corticosteroids. We tentatively conclude that haemostatic abnormalities and vascular changes, which must be caused by SLE itself, corticosteroid treatment, and young ages, may all, in part, contribute to the pathogenesis of ANB in SLE.
